Azithromycin ophthalmic solution, 1% + Vehicle

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Blepharitis

Conditions

Blepharitis

Trial Timeline

Dec 1, 2010 → Jun 1, 2011

NCT ID

NCT01269658

About Azithromycin ophthalmic solution, 1% + Vehicle

Azithromycin ophthalmic solution, 1% + Vehicle is a phase 2 stage product being developed by Merck for Blepharitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01269658. Target conditions include Blepharitis.

What happened to similar drugs?

5 of 10 similar drugs in Blepharitis were approved

Approved (5) Terminated (1) Active (4)

✅Lotilaner ophthalmic solution, 0.25% + Vehicle controlTarsus PharmaceuticalsApproved

✅AzaSite®MerckApproved

🔄TP-03 + TP-03 VehicleTarsus PharmaceuticalsPhase 3

🔄Lotilaner + Vehicle ControlLianBioPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01269658	Phase 2	Terminated	Dec 1, 2010	Jun 1, 2011	Blepharitis

Competing Products

15 competing products in Blepharitis

See all competitors

Product	Company	Stage	Hype Score
Lotilaner ophthalmic solution, 0.25% + Vehicle control	Tarsus Pharmaceuticals	Approved	37
TP-03 + TP-03 Vehicle	Tarsus Pharmaceuticals	Phase 3	34
TP-03, 0.25% + TP-03 Vehicle	Tarsus Pharmaceuticals	Phase 2/3	32
Lotilaner + Vehicle Control	LianBio	Phase 3	30
ISV-305	Sun Pharmaceutical	Phase 3	40
ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined) + Azasite + Dexamethasone	Sun Pharmaceutical	Phase 3	40
AzaSite®	Merck	Approved	43
AzaSite®	Merck	Approved	43
AzaSite®	Merck	Approved	43
Azithromycin ophthalmic solution, 1% + Placebo	Merck	Phase 2	35
AzaSite®	Merck	Approved	43
Azithromycin ophthalmic solution, 1% + Placebo	Merck	Phase 2	35
Pimecrolimus 0.3% Ophthalmic Ointment + Placebo Ophthalmic Ointment	Viatris	Phase 3	29
GLK-321 low dose BID + GLK-321 mid dose BID + GLK-321 high dose BID + GLK-321 high dose QD + Placebo BID	Glaukos	Phase 2	39
KPI-121 + Vehicle	Kala Pharmaceuticals	Phase 2	25